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CANCER MECHANISMS
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An estimated 15 percent of all human
cancers worldwide may be attributed to
viruses [1], representing a significant por-
tion of the global cancer burden. Both DNA
and RNA viruses have been shown to be
capable of causing cancer in humans. Ep-
stein-Barr virus, human papilloma virus,
hepatitis B virus, and human herpes virus-
8 are the four DNAviruses that are capable
of causing the development of human can-
cers. HumanTlymphotrophic virus type 1
and hepatitis C viruses are the two RNA
viruses that contribute to human cancers.
Close study of viruses and human can-
cer has led to optimism for the develop-
ment of new strategies for the prevention
of the preceding infection that can lead to
carcinogenesis. The presence of viral gene
products in tumor cells that require them to
maintain their unchecked proliferation also
can provide important targets for directed
therapies that specifically can distinguish
tumor cells from normal cells.The inability
of traditional cancer therapy, such as
chemotherapy and radiation, to distinguish
cancer cells from normal cells is a signifi-
cant drawback and leads to toxicities for
patients undergoing treatment. Targeted
therapies directed against viral proteins or
generate immune responses in order to ei-
ther prevent infection or kill infected cells
or cancer cells hold much promise for more
effective and tolerable strategies.
Human tumor viruses
Although it is convenient to consider
human tumor viruses as a discrete group of
viruses, these six viruses, in fact, have very
different genomes, life cycles, and repre-
sent a number of virus families. The path
from viral infection to tumorgenesis is slow
and inefficient; only a minority of infected
individuals progress to cancer, usually
years or even decades after primary infec-
tion. Virus infection also is generally not
sufficient for cancer, and additional events
and host factors, such as immunosuppres-
sion, somatic mutations, genetic predispo-
sition, and exposure to carcinogens must
also play a role.
Hepatitis B and C viruses
Hepatitis C virus is an enveloped RNA
virus of the flavivirus family. It is capable
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in humans by infecting liver cells. It is esti-
mated that approximately 3 percent of the
world’s population are hepatitis C carriers
[2]. Chronic infection with hepatitis C virus
results in cirrhosis, which in turn can lead to
primary hepatocellular carcinoma. Between
1 and 2 percent of infected patients with sub-
sequent compensated cirrhosis will develop
primary hepatocellular carcinoma per year
[3]. Transmission of the virus occurs
through the blood, with shared needles in in-
travenous drug abuse, sexual activity, and
parturition being the primary routes.
The hepatitis B virus of the family he-
padnaviridae is, by contrast, a DNA virus,
but the features of its resulting disease share
many similarities with hepatitis C virus.
Hepatitis B virus also is a blood-borne
pathogen that can result in acute and chronic
hepatitis. Chronic hepatitis, that is infections
lasting more than three months, can lead to
cirrhosis and liver failure. Chronic infection
also can lead to the development of hepato-
cellular carcinoma [4]. Hepatitis B infec-
tions is a significant global health problem
with an estimated 2 billion people infected
and 1.2 million deaths per year attributed to
subsequent hepatitis, cirrhosis and hepato-
cellular carcinoma [5].
Hepatocellular carcinoma is an aggres-
sive tumor that can occur in the setting of
liver disease resulting from infections with
hepatitis B and/or hepatitis C virus, although
the exact mechanism of oncogenesis by
these viruses is unclear. Diagnosis is usually
made late in the course of liver disease and
median survival ranges from six to 20
months after that time [6]. The traditional
foundation of treatment is surgical, whether
tumor resection or transplantation. However,
nonsurgical options such as percutaneous
ethanol injection, transarterial embolization,
radiofrequency ablation, chemotherapy, and
radiotherapy are also utilized.The choice of
therapies frequently depends on the extent
of disease and the amount of liver function
the patient has in reserve [7,8].
Research into novel therapies have fo-
cused on the use of virally targeted and im-
munological strategies with an eye on
preventing infection. Unfortunately, hepati-
tis C virus has proved to be poorly suited to
vaccines because its genome possesses a
very high mutation rate, especially in the hy-
pervariable region of the genome coding for
the envelope proteins allowing it to escape
immune recognition and elimination by the
host. There are 11 distinct genotypes and
several subtypes identified.
The introduction of vaccines against
hepatitis B virus in the early 1980s marked
a major milestone with what might be con-
sidered the first cancer prevention vaccine,
although the primary goal of this vaccine
was to prevent hepatitis. Since that time,
more than 110 countries have adopted a uni-
versal policy of immunizing all newborns,
according to the World Health Organzation.
Additionally, countries that have success-
fully implemented this program signifi-
cantly have decreased the carrier rate and
infection in their populations [9]. However,
vaccine coverage is often low in many de-
veloping countries due to the cost, lack of
heath care infrastructure for delivery of the
vaccine, and the need for three needle injec-
tions over six months. Even in some devel-
oped nations, universal vaccination has not
been implemented because of the belief that
it is a limited public health problem and the
expense is not justified [10,11].
New challenges for combating hepatitis
B infection center around efforts to address
the limitations of the current vaccine: the
need for multiple injections, the presence of
up to 10 percent nonresponders to the vac-
cine, the discovery of hepatitis B virus S
gene escape mutants in infants that were in-
fected despite an adequate response to the
vaccine, and the cost for developing nations.
The current multiple dosing schedule is
being addressed with attempts to combine it
with other required vaccines or decrease the
number of doses. Oral vaccination also is
being investigated as a way to obviate the
need for trained personnel to administer in-
jections.TheWorld Health Organization es-
timates that from $8 to $12 billion will be
needed to immunize children from the poor-
est countries from 2005-2010, which has
prompted efforts from public and private or-
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the need.
Medical therapy for patients infected
with hepatitis B has focused on the use of
interferon to reduce viral replication, which
decreases the incidence of life-threatening
liver complications in patients who respond
to the treatment [12]. Interferon alpha treat-
ment is effective in 20 to 30 percent of cases
in inducing loss of the hepatitis B e antigen.
However, the impact of interferon therapy
on subsequent hepatocellular carcinoma
rates is less clear [13,14]. Interferon therapy
is also limited by cost and side effects.
The limitations of interferon therapy
have been partly circumvented with the use
of targeted antiviral agents. Lamivudine has
been shown in a large multicenter random-
ized placebo-controlled trial to be effective
in reducing both the incidence of hepatic de-
compensation and the risk of hepatocellular
carcinoma [15]. Other antiviral agents con-
tinue to join the armamentarium; lamivu-
dine, adefovir, entecavir, and telbivudine
have been shown to be effective in hepatitis
B disease. These agents are nucleotide ana-
logues that exploit the need for the hepatitis
B virus to use reverse transcriptase to repli-
cate viral DNA. Since these agents specifi-
cally target the viral replication machinery
and are given orally, they are better toler-
ated. However, it has been observed that
long-term therapy with lamivudine can lead
to the emergence of genotypic resistance
mutations [16], but this does not negate the
benefits of lamivudine therapy in reducing
the rates of hepatocellular carcinoma [15].
The success of these therapies has reached
the point where patients with advanced cir-
rhosis secondary to hepatitis B can be
treated and transplanted without the devel-
opment of hepatitis B in the transplanted
liver.
Medical treatment of infection with
hepatitis C has not progressed at the same
speed. Pegylated interferon with ribavirin,
an antiviral agent that may act as a nucleo-
side analogue and inhibitor of RNAdepend-
ent RNApolymerase, has been shown to be
successful in eradicating infection in half of
patients [17]. However, therapy is expensive
and side effects are significant. Phase II tri-
als of oral antivirals such as protease in-
hibitors and polymerase inhibitors are
currently under way [18]. Unlike hepatitis
B, treatment of hepatocellular carcinoma
due to hepatitis C infection with transplanta-
tion almost always results in recurrent infec-
tion of the transplanted liver [19].
The search for targeted therapies that
can block hepatitis C viral replication by se-
lectively inhibiting viral replication has for
many years been hampered by the lack of
experimental infection systems, in either cell
culture or animal models to test candidate
therapies. The recent development of viral
replicons, subgenomic RNAs that are ex-
pressed and autonomously replicate within
cells, has led to the use of hepatitis C viral
replicons that can replicate in human he-
patoma cells lines [20] and the development
of mouse models of the disease [21,22].
These advances may herald more rapid
progress in the development of virally tar-
geted therapies such as hepatitis C virus spe-
cific protease and polymerase inhibitors.
Epstein-Barr virus (EBV) and human
herpesvirus 8 (HHV-8)
EBV and HHV-8 (also known as Ka-
posi sarcoma herpesvirus) are both her-
pesviruses that possess large
double-stranded DNAgenomes.As with all
herpesviruses, they encode enzymes in-
volved in DNA replication and repair and
nucleotide biosynthesis.They also both pos-
sess the ability to establish latency in B lym-
phocytes and reactivate into the lytic cycle.
Both also are associated with naturally oc-
curring tumors in humans.
EBV is a ubiquitous virus that is most
commonly known for being the primary
agent for infectious mononucleosis. Up to
95 percent of all adults are estimated to be
seropositive, and most EBV infections are
subclinical. EBV also is associated with a
number of malignancies: B and T cell lym-
phomas, Hodgkin’s disease, post-transplant
lymphoproliferative disease, leiomyosarco-
mas, and nasopharyngeal carcinomas. Of
these cancers, Burkitt’s lymphoma, post-
transplant lymphoproliferative disease, and
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quency in patients with immunodeficiency,
suggesting a role for immunosurveillance in
the suppression of malignant transformation.
The primary site of infection is the
oropharyngeal cavity, and EBVis capableof
infectingbothBcellsandepithelialcellsand
switching between the two [23]. The major
surfaceglycoprotein,gp350/220,bindstothe
cd21 receptor on B cells. Transformation of
B cells is a highly efficient process requiring
a large portion of the EBV genome, which
becomes circular for replication and latency.
Virus will directly enter the latent gene ex-
pression state with suppression of the lytic
cycle. Production of a number of latent gene
products are required for immortaliztion.
Immune therapy of EBV-associated tu-
mors has been target of research since stan-
dard therapy generally has entailed the use
of multi-agent chemotherapy, radiation ther-
apy, and surgery. This work has centered
around adoptive transfer of EBV-specific
cytotoxicT-cells [24,25] and shown success
but must overcome obstacles such as poten-
tial graft vs. host disease and resistance due
to mutation of selected EBV epitopes [26].
Vaccines capable of preventing primary
EBV infection or boosting immune re-
sponses against EBV-associated tumors are
under investigation. Much of the develop-
ment thus far has focused on gp350/220 sub-
unit vaccines [27], since it is one of the most
abundant proteins on the virus coat and also
the protein against which the human EBV
neutralizing antibody response is directed
[28]. Another strategy involves the use of a
recombinant vaccinia viral vector to express
an EBV membrane antigen [29].Asuccess-
ful vaccine would have the greatest impact
in regions of the world that have an espe-
cially high incidence of specific malignan-
cies. Burkitt’s lymphoma is the most
common childhood malignancy in the cen-
tral part of Africa where EBV and malaria
are considered cofactors in its carcinogene-
sis and 95 percent of children are infected
by age 3, compared to the United States,
where infection is usually delayed until ado-
lescence [30]. Nasopharyngeal carcinoma is
relatively rare but has an exceptionally high
incidence in southern China, approaching
more than 20 times greater than that of most
populations [31].
In 1994, HHV-8 DNAwas identified in
biopsies from tumors of a patient with Ka-
posi sarcoma [32], a relatively rare malig-
nancy prior to the AIDS epidemic. In
addition to it likely being an essential cofac-
tor for the development of Kaposi sarcoma,
HHV-8 also is believed to have a role in
Castleman’s disease and primary effusion
lymphoma [33]. The viral genome is ex-
pressed in these tumors and encodes trans-
forming proteins and anti-apoptotic factors.
The virus is also able to enhance the prolif-
eration of microvascular endothelial cells
[34].As with EBV, the predominant infected
cell is the B lymphocyte, although here the
lytic cycle is embraced rather than re-
pressed. This may play a crucial role in the
pathogenesis of Kaposis sarcoma by elabo-
ration of viral and host cytokines promoting
cell proliferation, angiogenesis, and en-
hancement of viral spread.
Targeted antiviral agents such as ganci-
clovirdirected againstviralDNAreplication
have had a dramatic affect on decreasing the
incidence of Kaposi sarcoma in AIDS pa-
tients through both therapy and prophylaxis
[35]. Ganciclovir is phosphorylated into a
GTP analog, which acts as a competive in-
hibitor of viral DNApolymerase resulting in
termination of viral DNA elongation. Fur-
thermore, a G protein coupled receptor
(vGPCR) has been identified as aviral onco-
geneinHHV-8infectedcellsthatcanexploit
cell signaling pathways to induce transfor-
mation and angiogenesis [36]. vGPCR also
has been proposed as a target for novel mo-
lecular therapies because of its key role in
disease progression [37]. But the therapy
regimen most responsible for the decreasing
incidenceofKaposisarcomamaywellbethe
success of highly active antiretroviral ther-
apy (HAART) regimens targeting HIV [38],
since it was the emergence ofHIVthat led to
the increasing incidence of Kaposi sarcoma.
Human papillomavirus (HPV)
HPV are small non-enveloped DNA
tumor viruses that commonly cause benign
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infection with high-risk subtypes of human
papillomavirus (HPV) is associated with the
development of cervical cancer [39]. HPV
infects epithelial cells, and, after integration
in host DNA, the production of oncopro-
teins, mainly E6 and E7, disrupts natural
tumor suppressor pathways and is required
for proliferation of cervical carcinoma cells
[40]. HPV also is believed to play a role in
other human cancers, such as head and neck
tumors, skin cancers in immunosuppressed
patients, and other anogenital cancers.
Cervical cancer is the second leading
cause of cancer mortality in women world-
wide, causing 240,000 deaths annually [41].
Of approximately 490,000 cases reported
each year, more than 80 percent occur in the
developing world, where effective but costly
Pap smear screening programs are not in
place [41]. Early precancerous changes and
early cancers detected by Pap smears are ef-
fectivelytreatedandcuredwithsurgicalther-
apy or ablation. In the absence of effective
screening, the disease is detected late.Tradi-
tional therapeutic options for cervical cancer
that have advanced beyond definitive surgi-
caltreatmentarechemotherapyandradiation
therapy,whichareassociatedwithmanytox-
icities and do not offer a lasting cure.
The immune system plays an important
role in the prevention of persistent HPV in-
fection and progression of precancerous le-
sions. Human papillomavirus is a poor
natural immunogen; as a double stranded
DNA virus, there is no RNA intermediate,
nor does infection cause cytolysis, allowing
initiation of innate immune responses [42].
HPV mainly encodes non-secreted nucleo-
proteins, which are poorly cross-presented
and compared to other viruses its non-struc-
tural proteins are expressed at low levels.
However, genital infection with HPVis usu-
ally transient.Additionally, inadequateTcell
responses may lead to failure to clear HPV-
infected cells. AIDS patients, renal trans-
plant patients receiving immunosuppressive
therapy, and individuals withTcell deficien-
cies have increased rates of HPV persist-
ence, anogenital lesions, and cervical cancer
[43-46].
In 2006, an effective prophylactic vac-
cine against HPV 16 and 18 based on virus-
like particles (VLP) of recombinant L1, the
major capsid protein [47,48], was approved
for use by the FDA based on clinical trials
that demonstrated nearly 100 percent protec-
tion from persistent infection through the
generation of high levels of neutralizing an-
tibodies. Since these types are the causative
agent of approximately 70 percent of cervi-
cal cancers, development of such an effec-
tive vaccine holds much promise for the
prevention of cervical cancer [47]. However,
the vaccine currently costs $360 for a com-
plete course of three injections given over
six months, does not provide protection
against other high risk HPV types, will pre-
sumably have limited benefit to women al-
ready infected, and has an unknown duration
of protection.
Because of these limitations, therapeu-
tic vaccination is being explored to treat
women already infected and accelerate the
impact of prophylactic vaccination in de-
creasing cervical cancer incidence. Tradi-
tional therapy for early cervical cancer and
precancerous lesions involves surgical exci-
sion or ablation. Therapeutic vaccination
seeks to generate a population of cytoxic T
cells that will recognize and kill tumor cells.
Since patients with T cell deficiencies are
known to be more susceptible to HPVinfec-
tion and disease progression, boostingTcell
responses to HPV may be crucial to a thera-
peutic immune strategy. In the case of cervi-
cal cancer, E6 and E7 oncoproteins are
expressed in all malignancies and are not
found in uninfected normal cells.Therefore,
they represent ideal targets for a therapeutic
immune response.Anumber of strategies to
generate immune responses against these
antigens are under investigation. Viral and
bacterial vectors have been used in mouse
models to generate immune responses. Vac-
cinia virus delivery of HPV 16 and 18 mod-
ified E6 and E7 proteins has demonstrated
safety and specific immune responses in
early clinical trials [49]. DNA vaccination
strategies also are under active investigation,
and several are in various stages of clinical
trials.Vaccination with plasmid DNAencap-
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shown histological and immunological re-
sponses when used to treat patients with
high grade cervical dysplasia [50-52].
Human T lymphotropic virus type I
(HTLV-1)
HTLV-1 is a slow transforming, single
strandedRNAretrovirusandisassociatedwith
adult T-cell leukemia [53]. It possesses a
diploid genome similar to other retroviruses:
two long terminal repeats flanking gag, pol,
and env genes as well as a number of acces-
sorygenes.HTLV-1hasaworldwidedistribu-
tion,withanestimated12to25millionpeople
infected.However,diseaseisonlyobservedin
lessthan5percentofinfectedindividuals.Itis
transmittedthroughbloodtransfusions,sexual
contact, and during parturition. HTLV-1 dis-
plays a special tropism for CD4 cells, which
clonally proliferate in adult T cell leukemia,
though how this is effected is not known.
HTLV-1 infection has a very long la-
tencyperiodof20to30years,butoncetumor
formation begins, progression is rapid. Stan-
dard chemotherapy often can bring about an
initial response with a partial or complete re-
mission; however, relapse is common, and
median survival is eight months. The HTLV-
1Taxgenehasbeenpostulatedtoplayanim-
portant role in tumorgenesis [54] through the
activation of viral transcription and the hi-
jacking of cellular growth and cell division
machinery, but the mechanisms leading to
adultTcellleukemiaarenotwellunderstood.
It has been suspected that HTLV-1 infection
maynotbesufficienttotransform,andrecent
evidence suggests that the decreased diver-
sity, frequency, and function of HTLV-1 spe-
cific CD8 T cells in the host may play an
important part in the development of adultT-
cell leukemia [55].Therefore, targeted thera-
pies using peptide, recombinant protein,
DNA, and viral vectors with the goal of gen-
erating neutralizing antibody against HTLV-
1 and multivalent cytotoxic T cell response
against Tax are under investigation [56].
Summary
The viruses reviewed here illustrate the
diverse biological pathways to malignancy
and the challenges of treating the resulting
diseases. Yet the presence of the viral gene
products in cancer and precancerous cells
present attractive targets that may be ex-
ploited in novel therapies that distinguish
these cells from normal cells. Antivirals
such as lamuvidine used in heptatitis B and
ganciclovir for Kaposi sarcoma specifically
target the viral replication machinery. Tar-
geting cancer cells specifically would have
advantages over traditional modalities such
as chemotherapy and radiation, which can
include significant toxicities. Cervical can-
cer, because it retains HPV viral oncopro-
teins E6 and E7 and requires their continued
expression for proliferation, provides an
ideal model for cytotoxic immune therapies
against these known antigens.
Given the prevalence of these cancers
in the developing world and the limitations
of health care infrastructure, strategies for
vaccine design to prevent primary infection
and targeted therapies for the treatment of
disease must be carefully considered in this
context. Use of needles, refrigeration, mul-
tiple doses, and cost are all significant barri-
ers to the delivery of an effective vaccine
[41]. Cost, need for trained personnel and
sophisticated equipment and facilities may
impede global use of the most advanced tar-
geted therapies. These challenges suggest
that exploration of prophylactic strategies
and development of specific, targeted thera-
pies are both necessary to decrease this por-
tion of the global cancer burden.
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